EirGenix Inc. (TPE:6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
57.30
+0.30 (0.53%)
At close: Apr 2, 2026
Market Cap17.34B -24.9%
Revenue (ttm)1.01B -0.4%
Net Income-760.55M
EPS-2.51
Shares Out302.65M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume422,426
Average Volume522,867
Open57.00
Previous Close57.00
Day's Range57.00 - 58.40
52-Week Range52.70 - 84.30
Beta0.67
RSI46.94
Earnings DateMay 8, 2026

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 1,000
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2025, EirGenix's revenue was 1.01 billion, a decrease of -0.38% compared to the previous year's 1.01 billion. Losses were -760.55 million, 8.91% more than in 2024.

Financial Statements